GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » FCF Yield %

Alaunos Therapeutics (Alaunos Therapeutics) FCF Yield % : -143.56 (As of Apr. 27, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Alaunos Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Alaunos Therapeutics's Trailing 12-Month Free Cash Flow is $-30.34 Mil, and Market Cap is $21.14 Mil. Therefore, Alaunos Therapeutics's FCF Yield % for today is -143.56%.

The historical rank and industry rank for Alaunos Therapeutics's FCF Yield % or its related term are showing as below:

TCRT' s FCF Yield % Range Over the Past 10 Years
Min: -276.51   Med: -11.15   Max: 1.33
Current: -143.56


During the past 13 years, the highest FCF Yield % of Alaunos Therapeutics was 1.33%. The lowest was -276.51%. And the median was -11.15%.

TCRT's FCF Yield % is ranked worse than
88.65% of 1550 companies
in the Biotechnology industry
Industry Median: -15.535 vs TCRT: -143.56

Alaunos Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -738,500.00%.


Alaunos Therapeutics FCF Yield % Historical Data

The historical data trend for Alaunos Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics FCF Yield % Chart

Alaunos Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.79 -12.35 -27.50 -18.87 -178.66

Alaunos Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.57 -24.91 -23.26 -80.40 -173.96

Competitive Comparison of Alaunos Therapeutics's FCF Yield %

For the Biotechnology subindustry, Alaunos Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alaunos Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's FCF Yield % falls into.



Alaunos Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Alaunos Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-30.339 / 16.98125625
=-178.66%

Alaunos Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-7.385 * 4 / 16.98125625
=-173.96%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alaunos Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Alaunos Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alaunos Therapeutics (Alaunos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8030 El Rio Street, Houston, TX, USA, 77054
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.
Executives
Boyle Kevin S. Sr. director, officer: Chief Executive Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Robert Hofmeister director C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Jaime Vieser director ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129
Robert W Postma director 141 MECOX ROAD, WATER MILL NY 11976
Michael Wong officer: VP, Finance C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Abhishek K Srivastava officer: See Remarks C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Holger Weis director C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Christopher Bowden director 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Mary Thistle director C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Drew Deniger officer: VP, Research & Development C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Groot Eleanor De officer: EVP, Operations C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Melinda Lackey officer: Senior Vice President, Legal C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054
Heidi Hagen director AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105
Raffaele Baffa officer: Chief Medical Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129

Alaunos Therapeutics (Alaunos Therapeutics) Headlines

From GuruFocus

Alaunos Therapeutics Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 07-05-2022